Skip to content
10-Q

Quarterly Report

CUMBERLAND PHARMACEUTICALS INC CPIX

0001628280-25-024342

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 6, 2025 14.96M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $15.11M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $17.96M
Stockholders Equity Q1 2025 · Mar 31, 2025 $28.66M
Stockholders Equity Q1 2025 · Dec 31, 2024 $22.85M
Current Liabilities Q1 2025 · Mar 31, 2025 $25.52M
Current Liabilities Q1 2025 · Dec 31, 2024 $31.62M
Total Liabilities Q1 2025 · Mar 31, 2025 $41.6M
Total Liabilities Q1 2025 · Dec 31, 2024 $53.04M
Current Assets Q1 2025 · Mar 31, 2025 $31.88M
Current Assets Q1 2025 · Dec 31, 2024 $36.45M
Total Assets Q1 2025 · Mar 31, 2025 $69.94M
Total Assets Q1 2025 · Dec 31, 2024 $75.58M
Shares Diluted Q1 2025 · Mar 31, 2024 14.1M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $247.61K
Capex Q1 2025 · Mar 31, 2024 $41.62K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$2.14M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.14
Eps Basic Q1 2025 · Mar 31, 2024 −$0.14
Sga Expense Q1 2025 · Mar 31, 2024 $2.37M
Rd Expense Q1 2025 · Mar 31, 2024 $1.16M
Net Income Q1 2025 · Mar 31, 2024 −$1.95M
Operating Income Q1 2025 · Mar 31, 2024 −$1.87M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $1.58M
Revenue Q1 2025 · Mar 31, 2024 $8.5M